跳至主要内容
临床试验/EUCTR2007-001776-36-IT
EUCTR2007-001776-36-IT进行中(未招募)不适用

A randomized, multicenter study, evaluating efficacy, safety, tolerability and pharmacokinetics of AEB071 combined with tacrolimus or mycophenolate mofetil (MMF) vs a tacrolimus-based control regimen in de novo liver transplant recipients - ND

OVARTIS FARMA0 个研究点目标入组 320 人开始时间: 2009年1月7日最近更新:
适应症
相关药物

试验速览

阶段
不适用
状态
进行中(未招募)
发起方
OVARTIS FARMA
入组人数
320

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • Ability and willingness to provide written informed consent and adhere to study regimen Male and female patients of any race, 18 years or older De novo recipients of a primary orthotopic liver transplant from a deceased donor HCV-positive and HCV-negative recipients
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range
  • F.1.3 Elderly (>=65 years) yes
  • F.1.3.1 Number of subjects for this age range

排除标准

  • Recipient criteria Prior organ/cellular transplants or of multiple organ transplants Anti-HIV-positive. Laboratory results obtained within 6 months prior to transplantation are acceptable ABO incompatible allograft MELD-score > 35 within 1 month prior to transplantation Serum creatinine of &#8805; 3.0 mg/dL ( &#8805; 265 &#956;mol/L) or on renal replacement therapy > 1 week Donor criteria Donor age < 12 years Partial (split liver allograft Living donor liver transplantation) Cardiac death donors (DCD) / non-heartbeating donors HIV positive donors HCV positive donors into HCV negative recipients HBsAg positive donors Cold ischemic time of >15 hours Macrosteatosis > 50% PLS SEE PROTOC.

研究者

发起方
OVARTIS FARMA

相似试验

进行中(未招募)
1 期
A randomized multicenter study evaluating efficacy, safety, tolerability and pharmacokinetics of AEB071 combined with tacrolimus or mycophenolate mofetil (MMF) vs. a tacrolimus-based control regimen in de novo liver transplant recipients.
EUCTR2007-001776-36-GBovartis Pharma Services AG
进行中(未招募)
不适用
Enterosgel® in the treatment of atopic dermatitis in adultsSkin and Connective Tissue DiseasesAtopic dermatitis
ISRCTN12307286Enteromed Ltd44
招募中
不适用
Home-based and group cognitive intervention programs in amnestic mild cognitive impairmentMental and behavioral disorders
KCT0000328Inha University Hospital270
招募中
3 期
A randomized, multicenter study to assess the efficacy on disease activity on enteric-coated mycophenolate sodium (EC-MPS, myfortic) versus continuation of azathioprine in patients with systemic lupus erythematosus on azathioprine maintenance therapy.lupusSLE10021460
NL-OMON30478Erasmus MC, Universitair Medisch Centrum Rotterdam48
进行中(未招募)
1 期
A randomized, multi-center study to assess the effect of Darbepoetin alfa (Aranesp®) for the treatment of anemia in patients with advanced hormone independent prostate cancer and anaemia - DANCAPepoIn an open randomised, multi-center study to identify the haematopoietic response to Aranesp® (Darbepoetin 6,75 mcg/kg) administrated every fourth week compared to standard care of treatment in patients with anaemia due to hormone refractory prostate cancer with progression of skeletal metastases. A haematopoietic response is defined as haemoglobin concentration > 12 g/dl or increase in haemoglobin > 2 g/dl during the treatment phase.MedDRA version: 6.1Level: PTClassification code 10038444
EUCTR2005-005658-37-DKDpt. of Urology -K. Aarhus University Hospital140
A randomized, multicenter study, evaluating... | 临床试验